Ligand director Jason Aryeh plans $222K share sale

Wells Fargo Clearing Services is identified as the broker, and Nasdaq is listed as the exchange for the proposed sale.

Available on EDGAR 11/02/2026 - 04:26 PM EST Accepted by SEC EDGAR 11/02/2026 - 04:26 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Ligand Pharmaceuticals Inc. (LGND) director Jason Aryeh filed a notice of intent to sell 700 shares of Class B common stock, with an aggregate market value of $221,595.09 and an approximate sale date of November 2, 2026.

Key Figures

Proposed sale quantity: 700 shares Aggregate market value: $221,595.09 Approximate sale date: November 2, 2026 +1 more

4 metrics

Proposed sale quantity 700 shares Class B common stock

Aggregate market value $221,595.09 Securities listed for sale

Approximate sale date November 2, 2026 Proposed sale

Acquisition period May 14, 2019–July 30, 2019 Period stated in remarks

Key Terms

Class B common, Secondary Market Purchase, Rule 144

3 terms

Class B common financial

"Class B common"

Secondary Market Purchase financial

"Secondary Market Purchase"

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many LGND shares does director Jason Aryeh plan to sell?

Director Jason Aryeh reported an intended sale of 700 shares of Class B common stock, with an aggregate market value of $221,595.09.

How did Jason Aryeh acquire the LGND shares listed for sale?

The acquisition information lists a secondary market purchase paid in cash, dated May 14, 2019. The remarks state that shares were acquired between May 14, 2019, and July 30, 2019.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001376960
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	LIGAND PHARMACEUTICALS INC
SEC File Number	001-33093
Address of Issuer	3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CALIFORNIA 92121
Phone	858-550-7500
Name of Person for Whose Account the Securities are To Be Sold	Aryeh Jason
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class B common	Wells Fargo Clearing Sevices 1 North Jefferson Avenue St. Louis MO 63103	700	221595.09	20002986	11/02/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class B common	05/14/2019	Secondary Market Purchase	Secondary Market			700	05/14/2019	cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	shares were acquired between 05/14/2019 to 07/30/2019.
Date of Notice	11/02/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Jason Aryeh
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)